| Targeting CD4+ Cells with Anti-CD4 Conjugated Mertansine-Loaded Nanogels M Canakci, K Singh, O Munkhbat, S Shanthalingam, A Mitra, M Gordon, ... Biomacromolecules 21 (6), 2473-2481, 2020 | 18 | 2020 |
| CD28 signaling drives notch ligand expression on CD4 T cells A Mitra, S Shanthalingam, HL Sherman, K Singh, M Canakci, JA Torres, ... Frontiers in Immunology 11, 735, 2020 | 17 | 2020 |
| A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance A Mitra, B Thompson, A Strange, CM Amato, M Vassallo, I Dolgalev, ... Clinical Cancer Research 29 (20), 4242-4255, 2023 | 9 | 2023 |
| Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion A Mitra, A Kumar, NP Amdare, R Pathak Biology 13 (5), 2024 | 6 | 2024 |
| LKB1 isoform expression modulates T cell plasticity downstream of PKCθ and IL-6 D Mohan, HL Sherman, A Mitra, R Lawlor, S Shanthalingam, J Ullom, ... Molecular Immunology 157, 129-141, 2023 | 2 | 2023 |
| Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749). T Mizutani, T Muramatsu, J Handzlik, D Kimono, A Mitra, E Yang, ... Journal of Clinical Oncology 42 (23_suppl), 222-222, 2024 | | 2024 |
| Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors P Sahu, A Mitra, A Ganguly International Review of Cell and Molecular Biology, 2024 | | 2024 |
| Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors P Sahu, A Mitra, A Ganguly International Review of Cell and Molecular Biology, 2024 | | 2024 |
| An immunosuppressive ectoenzyme-expressing T cell population is associated with non-responsiveness to immune checkpoint blockade in metastatic melanoma patients A Mitra, B Thompson, DM Woods, JS Weber Cancer Research 83 (7_Supplement), 2283-2283, 2023 | | 2023 |
| 1040 A population of ectoenzyme expressing T-cells with an immunosuppressive phenotype are associated with checkpoint immunotherapy resistance in metastatic melanoma patients D Woods, C Amato, A Strange, B Thompson, J Weber, A Mitra Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Correction to “Targeting CD4+ Cells with Anti-CD4 Conjugated Mertansine Loaded Nanogels” M Canakci, K Singh, O Munkhbat, S Shanthalingam, A Mitra, M Gordon, ... Biomacromolecules 22 (3), 1323-1323, 2021 | | 2021 |
| Abstract PO030: A Novel T-cell Population Expressing the Ectoenzymes CD38 and CD39 is Associated with Melanoma Patient Non-Response to Immunotherapy A Mitra, DM Woods, A Rao, AS Laino, A Winters, I Yanai, ... Cancer Immunology Research 9 (2_Supplement), PO030-PO030, 2021 | | 2021 |
| A Novel T-cell Population Expressing the Ectoenzymes CD38 and CD39 is Associated with Melanoma Patient Non-Response to Immunotherapy. A Mitra, DM Woods, A Rao, AS Laino, A Winters, I Yanai, ... CANCER IMMUNOLOGY RESEARCH 9 (2), 2021 | | 2021 |
| REGULATION OF NOTCH LIGAND EXPRESSION ON CD4 T CELLS A Mitra | | 2020 |
| Regulation of Notch activation in CD4+ T cells A Mitra, JA Torres, S Shanthalingam, J Vijayaraghavan, R Lawlor, ... The Journal of Immunology 200 (1_Supplement), 110.3-110.3, 2018 | | 2018 |
| AU Shabeer Ahamed A. Sarayu A. Bharathi A. Thangam A Vidya, A Jha, A Siddiqui, AM Khan, A Rahman, A Das, A Bhat, ... | | |
Sankaran ThayumanavanProfessor of Chemistry, University of Massachusetts AmherstGeverifieerd e-mailadres voor chem.umass.edu
